Organon & Co | OGN - Des Atouts

Prix De L'Action
11.26
Variation Quotidienne
2.66 30.93%
Mensuellement
84.59%
Annuel
-7.82%
Q2 Prévisions
11.02




Des Atouts Changement Date
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Celltrion KRW 21.08T 530.63B 2025-09
Cspc Pharmaceutical CNY 46.7B 695.56M 2025-12
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 530.92M 46.52M 2025-12
Divis Laboratories Ltd INR 181.51B 12.19B 2025-09
Gilead Sciences USD 59.02B 490M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Kangmei Pharma CNY 13.68B 38.19M 2025-09
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Merck USD 129.55B 12.02B 2025-09
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Organigram Holdings CAD 530.67M 31.54M 2025-12
Organon & Co USD 13.55B 52M 2025-09
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pharma Mar EUR 395.08M 53.42M 2025-12
Qiagen NV USD 6.3B 257.54M 2025-12
Sartorius EUR 9.87B 154.9M 2026-03
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Tilray USD 2.1B 15.95M 2025-09
Zealand Pharma A/S 15.95B 848.45M 2025-12